RU2068260C1 - Глазные капли - Google Patents
Глазные капли Download PDFInfo
- Publication number
- RU2068260C1 RU2068260C1 SU915001489A SU5001489A RU2068260C1 RU 2068260 C1 RU2068260 C1 RU 2068260C1 SU 915001489 A SU915001489 A SU 915001489A SU 5001489 A SU5001489 A SU 5001489A RU 2068260 C1 RU2068260 C1 RU 2068260C1
- Authority
- RU
- Russia
- Prior art keywords
- composition
- cyclodextrin
- compound
- eye drops
- drops
- Prior art date
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 24
- 229940012356 eye drops Drugs 0.000 title claims abstract description 24
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 16
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004327 boric acid Substances 0.000 claims abstract description 12
- 239000002738 chelating agent Substances 0.000 claims abstract description 12
- 239000006196 drop Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000012153 distilled water Substances 0.000 claims 1
- 206010015946 Eye irritation Diseases 0.000 abstract description 11
- 231100000013 eye irritation Toxicity 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 229960000583 acetic acid Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 71
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229960000686 benzalkonium chloride Drugs 0.000 description 14
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 14
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 239000002198 insoluble material Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- CLDJCRWXLDLJLO-UHFFFAOYSA-N 2-[2,8-di(propan-2-yl)-3-sulfanylidene-1,4-benzoxazin-4-yl]acetic acid Chemical compound C1=CC=C2N(CC(O)=O)C(=S)C(C(C)C)OC2=C1C(C)C CLDJCRWXLDLJLO-UHFFFAOYSA-N 0.000 description 4
- 206010007749 Cataract diabetic Diseases 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 201000007025 diabetic cataract Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010023365 keratopathy Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- APPOKADJQUIAHP-GGWOSOGESA-N (2e,4e)-hexa-2,4-diene Chemical compound C\C=C\C=C\C APPOKADJQUIAHP-GGWOSOGESA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- RYPKRALMXUUNKS-UHFFFAOYSA-N 2-Hexene Natural products CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical class [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- DPUXQWOMYBMHRN-UHFFFAOYSA-N hexa-2,3-diene Chemical compound CCC=C=CC DPUXQWOMYBMHRN-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP214827/90 | 1990-08-13 | ||
| JP21482790 | 1990-08-13 | ||
| JP162854/91 | 1991-07-03 | ||
| JP16285491 | 1991-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2068260C1 true RU2068260C1 (ru) | 1996-10-27 |
Family
ID=26488494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU915001489A RU2068260C1 (ru) | 1990-08-13 | 1991-08-12 | Глазные капли |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5663170A (enExample) |
| EP (1) | EP0472327B1 (enExample) |
| JP (1) | JP2769253B2 (enExample) |
| KR (1) | KR920003971A (enExample) |
| AT (1) | ATE121295T1 (enExample) |
| AU (1) | AU633754B2 (enExample) |
| CA (1) | CA2048942A1 (enExample) |
| DE (1) | DE69109021T2 (enExample) |
| DK (1) | DK0472327T3 (enExample) |
| ES (1) | ES2071227T3 (enExample) |
| FI (1) | FI97777C (enExample) |
| HU (1) | HU207950B (enExample) |
| NO (1) | NO177845C (enExample) |
| PT (1) | PT98643B (enExample) |
| RU (1) | RU2068260C1 (enExample) |
| TW (1) | TW200402B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2227740C2 (ru) * | 1999-06-11 | 2004-04-27 | Санкио Компани, Лимитед | Композиции, снижающие внутриглазное давление, для местного применения |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3926093A (en) * | 1992-03-18 | 1993-10-21 | Coopervision Pharmaceuticals, Inc. | Verapamil HC1 formulation and other ophthalmic solutions with buffer system for ocular administration |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| AU5599594A (en) * | 1992-11-16 | 1994-06-08 | Ciba-Geigy Ag | Polyvinyl alcohol/borate ophthalmic drug delivery system |
| US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
| SE501482C2 (sv) * | 1993-06-24 | 1995-02-27 | Leiras Oy | Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning |
| EP0711147A1 (en) * | 1993-07-28 | 1996-05-15 | Insite Vision Incorporated | Suspensions for delivery of medicament |
| US5631297A (en) * | 1994-07-11 | 1997-05-20 | Pate; David W. | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same |
| WO1996001558A1 (en) * | 1994-07-11 | 1996-01-25 | Pate David W | Anandamide analogue compositions and method of treating intraocular hypertention using same |
| JP3297969B2 (ja) * | 1994-12-26 | 2002-07-02 | ライオン株式会社 | 点眼剤 |
| US5929115A (en) * | 1995-01-20 | 1999-07-27 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drop |
| KR100261585B1 (ko) * | 1995-01-20 | 2000-07-15 | 오쿠다 기요아키 | 항염증점안제 |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2000012137A1 (en) * | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| JP2001125052A (ja) * | 1999-10-25 | 2001-05-11 | Lion Corp | コンタクトレンズ装着液 |
| US20030152631A1 (en) * | 2000-06-19 | 2003-08-14 | Santen Pharmaceutical Co., Ltd. | Aseptics |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6881726B2 (en) | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
| WO2006137433A1 (ja) * | 2005-06-21 | 2006-12-28 | Wakamoto Pharmaceutical Co., Ltd. | レボカバスチンを可溶化させた水性薬剤 |
| US20100069335A1 (en) * | 2005-07-15 | 2010-03-18 | Rajiv Bhushan | Prevention and Treatment of Ophthalmic Complications of Diabetes |
| AU2013241507A1 (en) | 2012-03-26 | 2014-10-09 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
| US11096958B2 (en) | 2018-04-27 | 2021-08-24 | Allergan, Inc. | Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity |
| EP4052694A4 (en) * | 2019-11-21 | 2023-09-20 | Samjin Pharmaceutical Co., Ltd. | Eye drop composition for preventing or treating eye disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU602641B2 (en) * | 1986-04-17 | 1990-10-18 | Senju Pharmaceutical Co., Ltd. | Thiolactam-N-acetic acid derivatives, their production and use |
-
1991
- 1991-07-29 TW TW080105889A patent/TW200402B/zh active
- 1991-08-05 JP JP3195186A patent/JP2769253B2/ja not_active Expired - Lifetime
- 1991-08-08 AT AT91307275T patent/ATE121295T1/de active
- 1991-08-08 AU AU81708/91A patent/AU633754B2/en not_active Ceased
- 1991-08-08 ES ES91307275T patent/ES2071227T3/es not_active Expired - Lifetime
- 1991-08-08 EP EP91307275A patent/EP0472327B1/en not_active Expired - Lifetime
- 1991-08-08 DE DE69109021T patent/DE69109021T2/de not_active Expired - Fee Related
- 1991-08-08 DK DK91307275.7T patent/DK0472327T3/da active
- 1991-08-12 RU SU915001489A patent/RU2068260C1/ru active
- 1991-08-12 CA CA002048942A patent/CA2048942A1/en not_active Abandoned
- 1991-08-12 NO NO913136A patent/NO177845C/no unknown
- 1991-08-12 FI FI913811A patent/FI97777C/fi not_active IP Right Cessation
- 1991-08-12 PT PT98643A patent/PT98643B/pt not_active IP Right Cessation
- 1991-08-13 HU HU912692A patent/HU207950B/hu not_active IP Right Cessation
- 1991-08-13 KR KR1019910013973A patent/KR920003971A/ko not_active Ceased
-
1992
- 1992-07-13 US US07/912,580 patent/US5663170A/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| US, Патент 4764360, 16.08.88, A 61K 9/08. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2227740C2 (ru) * | 1999-06-11 | 2004-04-27 | Санкио Компани, Лимитед | Композиции, снижающие внутриглазное давление, для местного применения |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200402B (enExample) | 1993-02-21 |
| KR920003971A (ko) | 1992-03-27 |
| PT98643A (pt) | 1992-07-31 |
| HU207950B (en) | 1993-07-28 |
| CA2048942A1 (en) | 1992-02-14 |
| NO913136D0 (no) | 1991-08-12 |
| EP0472327B1 (en) | 1995-04-19 |
| NO177845C (no) | 1995-12-06 |
| NO177845B (no) | 1995-08-28 |
| ATE121295T1 (de) | 1995-05-15 |
| EP0472327A1 (en) | 1992-02-26 |
| JP2769253B2 (ja) | 1998-06-25 |
| DE69109021D1 (de) | 1995-05-24 |
| AU8170891A (en) | 1992-02-20 |
| DE69109021T2 (de) | 1995-09-21 |
| FI97777C (fi) | 1997-02-25 |
| PT98643B (pt) | 1999-01-29 |
| US5663170A (en) | 1997-09-02 |
| NO913136L (no) | 1992-02-14 |
| HUT61196A (en) | 1992-12-28 |
| FI913811L (fi) | 1992-02-14 |
| ES2071227T3 (es) | 1995-06-16 |
| HU912692D0 (en) | 1992-01-28 |
| FI913811A0 (fi) | 1991-08-12 |
| FI97777B (fi) | 1996-11-15 |
| DK0472327T3 (da) | 1995-05-08 |
| JPH05213757A (ja) | 1993-08-24 |
| AU633754B2 (en) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2068260C1 (ru) | Глазные капли | |
| KR100889170B1 (ko) | 안구 건조의 치료에 있어서 리멕솔론의 용도 | |
| KR20140009332A (ko) | 고농도 올로파타딘 안과용 조성물 | |
| Loftsson et al. | Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits | |
| KR20140056280A (ko) | 비마토프로스트 및 브리모니딘의 고정된 용량 조합 | |
| JP2824863B2 (ja) | α▲下１▼―ブロッカー点眼剤 | |
| US5605892A (en) | Compositions of arginine amide with cyclodextrin of caffeine, and methods of use | |
| CA3001957C (en) | Ophthalmic solution of difluprednate | |
| JP2003206241A (ja) | 眼科用剤 | |
| KR102365008B1 (ko) | 디쿠아포솔을 포함하는 점안 조성물 | |
| JP2787131B2 (ja) | 水性懸濁液剤 | |
| EP4240364B1 (en) | OPHTHALMIC COMPOSITION CONTAINING LEVOFLOXACIN AND KETOROLAC, ITS PREPARATION PROCESS AND ITS USE | |
| US5561154A (en) | Treatment of acute urinary retention | |
| JP5019923B2 (ja) | プラノプロフェン含有医薬組成物 | |
| CA3201220A1 (en) | Difluprednate for reducing the adverse effects of ocular inflammation | |
| JP2946015B2 (ja) | 安定な抗ウィルス点滴用注射剤 | |
| US6110926A (en) | Eyedrop composition | |
| CN111743858B (zh) | 一种溴芬酸钠的药物组合物 | |
| US20070112041A1 (en) | Nicardipine injection composition | |
| JPH06511014A (ja) | 眼への投与に用いる、緩衝剤系を含有するベラパミル塩酸製剤などの眼科用液剤 | |
| FR2890561A1 (fr) | Composition ophtalmique contenant un sel de cysteamine | |
| FR2679137A1 (fr) | Nouvelles compositions pharmaceutiques a base d'un derive pregnenique et leur procede de preparation. |